205 related articles for article (PubMed ID: 1745483)
1. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
[TBL] [Abstract][Full Text] [Related]
2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
3. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
[TBL] [Abstract][Full Text] [Related]
4. Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report.
Ikeda K; Abe N; Morioka A; Inoo M; Nagai M; Kubota Y; Irino S
Jpn J Med; 1990; 29(5):516-8. PubMed ID: 2089176
[TBL] [Abstract][Full Text] [Related]
5. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Barlogie B; Velasquez WS; Alexanian R; Cabanillas F
J Clin Oncol; 1989 Oct; 7(10):1514-7. PubMed ID: 2778481
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
7. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
[TBL] [Abstract][Full Text] [Related]
8. Therapy of primary resistant and relapsed multiple myeloma.
Barlogie B; Alexanian R
Onkologie; 1986 Aug; 9(4):210-4. PubMed ID: 3531948
[TBL] [Abstract][Full Text] [Related]
9. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
[TBL] [Abstract][Full Text] [Related]
10. Biology and therapy of multiple myeloma.
Barlogie B; Alexanian R
Acta Haematol; 1987; 78 Suppl 1():171-4. PubMed ID: 3124442
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy and autologous bone marrow transplantation for myeloma.
McElwain TJ; Selby PJ; Gore ME; Viner C; Meldrum M; Millar BC; Malpas JS
Eur J Haematol Suppl; 1989; 51():152-6. PubMed ID: 2697587
[TBL] [Abstract][Full Text] [Related]
12. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
[TBL] [Abstract][Full Text] [Related]
13. Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen.
Stenzinger W; Blömker A; Hiddemann W; van de Loo J
Blut; 1990; 61(2-3):55-9. PubMed ID: 2207342
[TBL] [Abstract][Full Text] [Related]
14. High-risk multiple myeloma treated with high-dose melphalan.
Lokhorst HM; Meuwissen OJ; Verdonck LF; Dekker AW
J Clin Oncol; 1992 Jan; 10(1):47-51. PubMed ID: 1727925
[TBL] [Abstract][Full Text] [Related]
15. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
[TBL] [Abstract][Full Text] [Related]
16. [Progress in the treatment of multiple myeloma].
Wada M; Mizoguchi H
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
[TBL] [Abstract][Full Text] [Related]
17. Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).
Bladé J; San Miguel J; Sanz-Sanz MA; Alcalá A; Hernández JM; Martínez M; García-Conde J; Moro J; Ortega F; Fontanillas M
Eur J Cancer; 1992; 29A(1):57-60. PubMed ID: 1445746
[TBL] [Abstract][Full Text] [Related]
18. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors with high-dose melphalan for refractory multiple myeloma.
Barlogie B; Alexanian R; Smallwood L; Cheson B; Dixon D; Dicke K; Cabanillas F
Blood; 1988 Dec; 72(6):2015-9. PubMed ID: 3196876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
